Ovid Therapeutics Inc. Forecast, price target & analysts
Ovid Therapeutics Inc. Target price 2026 - Analyst rating & recommendation
Ovid Therapeutics Inc. Classifications & Recommendation
Ovid Therapeutics Inc. Price Target
| Target Price | $5.10 |
| Price | $2.40 |
| Potential |
112.50%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Ovid Therapeutics Inc. 2027 .
The average Ovid Therapeutics Inc. target price is $5.10.
This is
112.50%
register free of charge
$9.45
293.75%
register free of charge
$4.04
68.33%
register free of charge
|
|
| A rating was issued by 16 analysts: 15 Analysts recommend Ovid Therapeutics Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ovid Therapeutics Inc. stock has an average upside potential 2027 of
112.50%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.25 | 0.83 |
| 1,171.93% | 88.53% | |
| EBITDA Margin | -581.66% | -6,479.39% |
| 94.59% | 1,013.96% | |
| Net Margin | -240.14% | -8,434.09% |
| 94.82% | 3,412.19% |
12 Analysts have issued a sales forecast Ovid Therapeutics Inc. 2026 . The average Ovid Therapeutics Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Ovid Therapeutics Inc. EBITDA forecast 2026. The average Ovid Therapeutics Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-42.2m | 31.17% |
|---|---|---|
| 2026 |
$-53.9m
27.76%
unlock
|
|
EBITDA Margin
| 2025 | -581.66% | 94.59% |
|---|---|---|
| 2026 |
-6,479.39%
1,013.96%
unlock
|
|
12 Ovid Therapeutics Inc. Analysts have issued a net profit forecast 2026. The average Ovid Therapeutics Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.24 | -0.38 |
| 35.14% | 58.33% | |
| P/E | negative | |
| EV/Sales | 422.72 |
12 Analysts have issued a Ovid Therapeutics Inc. forecast for earnings per share. The average Ovid Therapeutics Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ovid Therapeutics Inc....
Current Ovid Therapeutics Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Apr 15 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 09 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Mar 26 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 20 2026 |
| LifeSci Capital |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Apr 15 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 09 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Mar 26 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 20 2026 |
|
Locked
LifeSci Capital:
Locked
➜
Locked
|
Dec 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
